Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM19 CAR-T Cells in R/R B-cell Acute Lymphoblastic Leukemia
NCT05480501Phase 1Unknown
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Jul 2022
- Primary completion
- Aug 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IM19 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Immunochina Pharmaceuticals. Primary endpoints: Incidence of adverse events (AEs) at 28 days and Persistence of CAR-T cells at 24 weeks. Status: unknown.
02
Drugs
IM19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05480501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05480501.